TOPISCAB 5% (permethrin), antiparasitic

DERMATOLOGY - New medicinal product
Opinions on drugs - Posted on Apr 09 2015

Reason for request


Minor improvement in the management of human scabies


  • TOPISCAB cream has Marketing Authorisation in the topical treatment of human scabies.
  • Its efficacy has been demonstrated compared with orally administered ivermectin. It is based on compliance with two skin applications 1 week apart.
  • This medicine can be used in children from 2 months of age and in pregnant women, populations not covered by the other currently available scabicides, in a context of an extended stock shortage of ASCABIOL. It offers a minor improvement in the treatment of human scabies.


Clinical Benefit



Clinical Added Value



Therapeutic use


Contact Us

Évaluation des médicaments